Navigation Links
Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals

BELGRADE, Mont., Oct. 22 /PRNewswire-FirstCall/ -- Bacterin International Holdings, Inc. (OTC Bulletin Board: BIHI) ("Bacterin"), a developer of anti-infective coatings for medical applications and revolutionary bone graft material, today announced that it has confirmed the appointment of Jon M. Wickwire, a distinguished Washington, D.C. based attorney and Michael A. Lopach, a CPA and founder of Lopach & Carparelli, to its Board of Directors.  Effective immediately, Mr. Wickwire will assume the duties of chairman of the Corporate Governance and Nominating Committees and Mr. Lopach has accepted the position as chairman of the Board's Audit Committee, while Mitch Godfrey, a longstanding Bacterin Board member will chair the Compensation Committee. The two new members replace departing members Daniel R. Frank, Gary M. Simon and Kenneth W. Calligar who recently stepped down from the Board due to personal reasons.    

"I want to thank our three departing Board members for their zealous attention and contribution to our launch as a public company.  We wish these gentlemen well in their future pursuits.  The addition of Michael Lopach, who comes with over 30 years of public accounting experience, reinforces our financial governance, while Jon Wickwire adds a strong legal and project structuring background to our board," commented Guy Cook, Bacterin's founder and CEO.  "During these early days as a public Board of Directors, it has become clear that an odd number of members to the Board is imperative to maintain the smooth operation of our company.  Consequently we stand today as a five member Board and heartily welcome Jon and Mike who we believe bring critical skills to our company as we enter an accelerated growth stage."

Jon Wickwire, an attorney and a founding shareholder of Wickwire Gavin, P.C., a national construction law firm which merged with Akerman Senterfitt, one of the top 100 law firms in the United States. Mr. Wickwire served as lead counsel on major infrastructure litigation and alternative dispute resolutions, both domestically and internationally, throughout his 35 year career.  He served as the founding chairman of the College of Scheduling, an organization dedicated to advancing the techniques, practice and profession of project scheduling.  Mr. Wickwire was the founding fellow of the American College of Construction Lawyers.  He was guest speaker at numerous industry conferences and authored several books and articles on construction and public contract law, including Construction Management: Law and Practice and The Construction Subcontracting Manual: Practice Guide with Forms.  Mr. Wickwire is a graduate of the University of Maryland and Georgetown University Law Center.

Michael Lopach spent 27 years of his career with Galusha, Higgens, Galusha & Co., the largest privately held accounting firm in Montana and northern Idaho, a firm establish in 1919 that employs 60 accounting professionals in six offices, where he served as president and CEO.  In 1999, Mr. Lopach founded Lopach & Carparelli PC, an accounting firm that focuses on medical practitioners. He is a certified public account and received his MBA from the University of Notre Dame.

Commenting on his appointment, Jon Wickwire said, "I have been an investor in Bacterin for over five years and am a firm believer in the company's future.  I see Bacterin as an industry leader in the field of biologics as well as coatings and consider my participation on the company's board as an opportunity to contribute to the cultivation of a meaningful advancement in bioactive coatings and allografts that will enrich the biologics industry, the medical community and the patients it serves."

About Bacterin International Holdings, Inc.

Bacterin International Holdings, Inc. ("Bacterin") develops, manufactures and markets biologics products to domestic and international markets.  Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth.  These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain by facet joint stabilization, promotion of bone fusion in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral bone defect repair in articulating joint surgeries.

Bacterin's Medical Device division develops anti-microbial coatings based upon proprietary coating technologies. Bacterin develops, employs, and licenses bioactive coatings for various medical device applications.  Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination on medical devices drug delivery, local (as opposed to systemic) pain management, and anti-thrombotic factors for medical device applications.  

Headquartered in Belgrade, Montana, Bacterin operates a 32,000 square foot, state-of-the-art, fully compliant and FDA registered facility, equipped with four "Class 100" clean rooms.  For further information please visit

This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. These forward-looking statements are based on current expectations or beliefs and include, but are not limited to, statements about the Company's earnings release and its expectations based on the results of second quarter of 2010, including reductions in expenses and increases in revenues due to among other things, the anticipated growth of its sales force. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability and willingness of third-party manufacturers to timely and cost-effectively fulfill orders from the Company; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

SOURCE Bacterin International Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Bacterin International Appoints Three New Members to Its Board of Directors
2. Indias Favorable and Progressive Regulatory Environment Causes Accelerated Growth of Max Neeman Internationals Regulatory Services
3. David P. Lang Appointed Vice President of CryoLife International, Inc.
4. YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
5. ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
6. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
7. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
8. Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference
9. Serono Symposia International Foundation (SSIF) Launches a New Web Site Dedicated to Medical Education on Phenylketonuria (PKU)
10. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
11. Nutrastar International Inc. Announces Record Second Quarter 2010 Results
Post Your Comments:
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):